India’s Zydus Lifesciences and its U.S. unit have agreed to pay $120 million to Astellas Pharma to resolve a patent dispute over the Japanese company’s bladder disorder drug, Mirabegron. Under the settlement, Zydus will also pay a pre-paid per-unit licensing fee for sales of its generic version in the U.S. until September 2027, allowing it […]Continue Reading
